More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.